These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD. Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582 [Abstract] [Full Text] [Related]
8. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M. Clin Cancer Res; 2009 Jan 01; 15(1):299-306. PubMed ID: 19118058 [Abstract] [Full Text] [Related]
9. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ. Eur J Immunol; 1997 May 01; 27(5):1115-23. PubMed ID: 9174600 [Abstract] [Full Text] [Related]
10. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Haematologica; 2002 Sep 01; 87(9):989-1001. PubMed ID: 12217812 [Abstract] [Full Text] [Related]
13. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G. Clin Cancer Res; 2005 Nov 01; 11(21):7891-900. PubMed ID: 16278414 [Abstract] [Full Text] [Related]
14. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Dai S, Wan T, Wang B, Zhou X, Xiu F, Chen T, Wu Y, Cao X. Clin Cancer Res; 2005 Oct 15; 11(20):7554-63. PubMed ID: 16243831 [Abstract] [Full Text] [Related]
15. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG. Clin Cancer Res; 1999 Dec 15; 5(12):4214-23. PubMed ID: 10632363 [Abstract] [Full Text] [Related]